Usa Financial Portformulas Has Upped Take (TTWO) Stake By $885,360; Ironwood Pharmaceuticals, Inc. (IRWD) Covered By 5 Bullish Analysts Last Week

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 5 have Buy rating, 1 Sell and 9 Hold. Therefore 33% are positive. Ironwood Pharmaceuticals had 35 analyst reports since August 6, 2015 according to SRatingsIntel. As per Wednesday, April 6, the company rating was upgraded by Cowen & Co. Mizuho maintained it with “Buy” rating and $16 target in Tuesday, May 10 report. As per Tuesday, June 6, the company rating was maintained by Mizuho. The stock has “Buy” rating by Mizuho on Friday, October 6. The company was maintained on Monday, August 21 by Cowen & Co. The firm earned “Neutral” rating on Monday, March 21 by Goldman Sachs. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Buy” rating given on Wednesday, November 1 by Cowen & Co. The rating was downgraded by Zacks on Monday, August 10 to “Hold”. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Neutral” rating given on Monday, October 24 by Wedbush. The rating was downgraded by J.P. Morgan to “Hold” on Friday, July 21. See Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) latest ratings:

06/12/2017 Broker: Mizuho Old Rating: Buy New Rating: Neutral Downgrade
04/12/2017 Broker: BTIG Research Rating: Buy New Target: $21.0
04/12/2017 Broker: Morgan Stanley Rating: Hold
27/11/2017 Broker: Credit Suisse Rating: Outperform New Target: $19 Initiates Coverage On
01/11/2017 Broker: Cowen & Co Rating: Buy New Target: $20.0 Maintain
06/10/2017 Broker: Mizuho Rating: Buy New Target: $20.0 Maintain
21/08/2017 Broker: Cowen & Co Rating: Buy New Target: $20.0 Maintain
04/08/2017 Broker: Cowen & Co Rating: Buy New Target: $20.0000 Maintain
02/08/2017 Broker: Mizuho Rating: Buy Maintain
21/07/2017 Broker: Wells Fargo Rating: Buy New Target: $19.0000

Usa Financial Portformulas Corp increased Take (TTWO) stake by 116.73% reported in 2017Q3 SEC filing. Usa Financial Portformulas Corp acquired 8,680 shares as Take (TTWO)’s stock rose 13.22%. The Usa Financial Portformulas Corp holds 16,116 shares with $1.65 million value, up from 7,436 last quarter. Take now has $12.30 billion valuation. The stock decreased 0.42% or $0.45 during the last trading session, reaching $107.8. About 962,790 shares traded. Take-Two Interactive Software, Inc. (NASDAQ:TTWO) has risen 81.23% since December 28, 2016 and is uptrending. It has outperformed by 64.53% the S&P500.

Investors sentiment decreased to 1.25 in 2017 Q3. Its down 0.06, from 1.31 in 2017Q2. It fall, as 24 investors sold Ironwood Pharmaceuticals, Inc. shares while 32 reduced holdings. 13 funds opened positions while 57 raised stakes. 154.60 million shares or 6.92% more from 144.60 million shares in 2017Q2 were reported. Financial Bank Of Mellon has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Ubs Asset Management Americas reported 6.41 million shares. Ameritas Inv Prtnrs reported 11,821 shares. Oppenheimer Asset Mngmt owns 23,405 shares. Broderick Brian C owns 144,476 shares or 0.82% of their US portfolio. Legal & General Group Public Ltd reported 55,707 shares. Hutchin Hill Ltd Partnership reported 0.11% stake. Bridger Mngmt Ltd Company has 2.4% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2.55 million shares. Evercore Wealth Mgmt Ltd Co accumulated 0.01% or 22,425 shares. Bnp Paribas Asset Mngmt Sa reported 0.24% stake. Penn Inc has 1.03% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 883,217 shares. Jane Street Grp Limited has 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Employees Retirement Systems Of Texas reported 105,000 shares stake. Wisconsin-based State Of Wisconsin Investment Board has invested 0.03% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Raymond James Fincl Service Advisors has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.31 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

It closed at $15.39 lastly. It is down 57.40% since December 28, 2016 and is uptrending. It has outperformed by 40.70% the S&P500.

Since August 18, 2017, it had 0 insider purchases, and 3 selling transactions for $59,508 activity. 1,500 shares valued at $24,240 were sold by McHugh Julie on Tuesday, September 5. Shares for $32,300 were sold by OLANOFF LAWRENCE S. Consylman Gina sold $2,968 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, August 18.

Usa Financial Portformulas Corp decreased Borgwarner Inc (NYSE:BWA) stake by 9,530 shares to 75,713 valued at $3.88M in 2017Q3. It also reduced Lear Corp (NYSE:LEA) stake by 2,069 shares and now owns 3,087 shares. Iac Interactivecorp (NASDAQ:IACI) was reduced too.

Since August 4, 2017, it had 0 insider purchases, and 4 sales for $7.68 million activity. 7,000 shares valued at $614,600 were sold by Dornemann Michael on Friday, August 4. On Thursday, August 10 Sheresky Michael sold $41,831 worth of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) or 465 shares. The insider ZELNICK STRAUSS sold 50,000 shares worth $4.39M. Another trade for 30,000 shares valued at $2.63 million was sold by Goldstein Lainie.